Drug Information

Drug General Information
Drug ID
D0A0MS
Former ID
DIB000348
Drug Name
BI 655066
Drug Type
Antibody
Indication Ankylosing spondylitis [ICD9: 720; ICD10:M08.1, M45] Phase 2 [525187]
Company
Boehringer ingelheim pharmaceuticals
Target and Pathway
Target(s) Interleukin-23 ligand Target Info [533178]
KEGG Pathway Cytokine-cytokine receptor interaction
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Jak-STAT signaling pathway
Type I diabetes mellitus
Pertussis
Legionellosis
Leishmaniasis
Chagas disease (American trypanosomiasis)
African trypanosomiasis
Malaria
Toxoplasmosis
Amoebiasis
Tuberculosis
Measles
Influenza A
Herpes simplex infection
Inflammatory bowel disease (IBD)
Allograft rejection
WikiPathways Toll-like receptor signaling pathway
Aryl Hydrocarbon Receptor Pathway
Allograft Rejection
Regulation of toll-like receptor signaling pathway
References
Ref 525187ClinicalTrials.gov (NCT02443298) Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma.. U.S. National Institutes of Health.
Ref 533178Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.